Gastric cancer patient who underwent LAPPG
Conditions
Interventions
Oral administration of rikkunshito (2.5g t.i.d) before or between meals for 77 days
Sponsors
The Cancer Institute Hospital of JFCR Gastroenterological Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Staging of gastric cancer is IA (UICC TNM classification) 2)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients with multiple cancer 2)Patients who have nutritional disorder before surgery 3)Patients whose main organ function is not working 4)Patients who had administration of other Kampo medicine 1 month prior to the administration of test drug 5)Patients with severe cardiac failure, acute inflammatory disease or other severe complications 6)Patients who are intolerant to oral administration 7) Patients who are pregnant, considering pregnancy or lactation 8)Patients with gastrointestinal bleeding, mechanical ileus, gastrointestinal perforation 9)Patients who has history of hypersensitivity toward Kampo medicine 10)Patients considered inappropriate by the study investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of anorexia and rate of body weight loss after LAPPG | — |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal pain, dyspepsia and other gastrointestinal symptoms. Nutritional factor. Safety of rikkunshito | — |
Countries
Japan
Outcome results
None listed